Literature DB >> 10859448

Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?

J Morote1, G Encabo, M López, I M de Torres.   

Abstract

OBJECTIVE: To analyze the utility of total/free prostate-specific antigen (PSA) and age as predictors of the prostate volume in men with symptomatic benign prostatic hyperplasia (BPH) and no evidence of prostate cancer. PATIENTS AND METHODS: Total and free serum PSA were determined in 681 patients with normal digital rectal examination and symptomatic BPH using the Hybritech method. Prostate volume was measured by transrectal ultrasound (TRUS). TRUS-guided biopsy was performed in 459 (67.4%) of the patients with a serum PSA >4.0 ng/ml.
RESULTS: The relationship with prostate volume was best described in a log linear fashion by free PSA (R(2) = 0.367), total PSA (R(2) = 0.264) and age (R(2) = 0.017). Multiple linear regression demonstrates no significant influence of age. Free PSA was able to predict the individual TRUS prostate volume +/-10% in 67% of the patients and +/-20% in 91.2% and total PSA in 63 and 90. 9%, respectively.
CONCLUSION: Prostate volume is strongly related with free and total PSA. Both determinations would be able to predict the TRUS prostate volume +/-20% in more than 90% of the patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859448     DOI: 10.1159/000020258

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  New technique for prostate volume assessment.

Authors:  Mohamad Habes; Jeanette Bahr; Thilo Schiller; Jens-Peter Kühn; Laura Hoppe; Martin Burchardt; Wolfgang Hoffmann
Journal:  World J Urol       Date:  2013-12-05       Impact factor: 4.226

Review 2.  [Diagnostics of benign prostate syndrome].

Authors:  M Seitz; A Herlemann; G Magistro; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

Review 3.  A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Authors:  Chris Mullins; M Scott Lucia; Simon W Hayward; Jeannette Y Lee; Jonathan M Levitt; Victor K Lin; Brian C-S Liu; Arul M Chinnaiyan; Mark A Rubin; Kevin Slawin; Robert A Star; Robert H Getzenberg
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

4.  Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia.

Authors:  Qiqi Mao; Xiangyi Zheng; Xiaolong Jia; Yuyong Wang; Jie Qin; Kai Yang; Yu Bai; Liping Xie
Journal:  Int Urol Nephrol       Date:  2009-02-18       Impact factor: 2.370

Review 5.  Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.

Authors:  Jonathan M Levitt; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

6.  Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.

Authors:  Ida Bagus O W Putra; Agus R A H Hamid; Chaidir A Mochtar; Rainy Umbas
Journal:  Prostate Int       Date:  2016-03-11

Review 7.  Molecular diagnosis of prostate cancer.

Authors:  Eduardo I Canto; Shahrokh F Shariat; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

8.  Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population.

Authors:  Hoon Choi; Jae Young Park; Ji Sung Shim; Jae Heon Kim; Jae Hyun Bae
Journal:  Int Neurourol J       Date:  2013-06-30       Impact factor: 2.835

9.  Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of korean men with biopsy-proven benign prostatic hyperplasia.

Authors:  Tae Yong Park; Ji Yun Chae; Jong Wook Kim; Jin Wook Kim; Mi Mi Oh; Cheol Yong Yoon; Du Geon Moon
Journal:  Korean J Urol       Date:  2013-09-10

10.  Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.

Authors:  Melissa M Norström; Emelie Rådestad; Berit Sundberg; Jonas Mattsson; Lars Henningsohn; Victor Levitsky; Michael Uhlin
Journal:  Oncotarget       Date:  2016-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.